At the Border, Not in Court
The EU-INDIA FTA and Generic Medicines
**Akshat Singh
The India-EU Free Trade Agreement negotiations ended in New Delhi on 27th January 2026. The process had begun in 2007 and had been interrupted several times. Both sides have described it as the largest trade agreement either has concluded. The political attention around the signing reflected that claim, including the joint appearance of EU and Indian leaders at the Republic Day parade. But the agreement has not yet entered into force.
Both sides still have to complete the legal changes, translations, and ratification process. This includes approval from the European Parliament and the Union Cabinet in India. Much of the commentary since January has treated the conclusion of negotiations as though the agreement were already law. It is not yet law. The text is finished, but domestic approval is still pending. That gives India some room to influence how the agreement will be implemented.
For India’s generic drug industry, the result is largely positive. There is still some reason for caution. The final text of this agreement neither contains Patent Term Extension nor Data exclusivity. These were the two provisions against which pharmaceutical groups had fought hardest. In March, Médecins Sans Frontières and the Delhi Network of Positive People welcomed the removal of provisions that went beyond TRIPS requirements. They also advised that enforcement should be done with careful attention.
India has also maintained its position on the patent issues that had dominated the argument for two decades. The less-discussed question is what will happen at ports and airports once the agreement takes effect? This especially matters for medicines merely passing through European territory on their way to another country.
What does the final agreement contain
The Indian government has made it clear that the IP chapter does not cover patent law. The Ministry of Commerce confirmed that there is no specific section relating to patents, no obligation to introduce data exclusivity, and no requirement to amend any of India’s intellectual property statutes. The chapter includes copyright, trademarks, geographical indications, industrial designs, trade secrets and undisclosed information, and plant variety protection. It also includes a general enforcement section and a reiteration of the Doha Declaration on TRIPS and Public Health. The European Commission’s own chapter-by-chapter summary refers to the enforcement section in just as broad a way, mentioning the measures, procedures, and remedies without giving patents any special treatment. There is no requirement to protect pharmaceutical marketing authorisation data beyond what is already allowed by Article 39.3 of TRIPS.
It by no means suggests that the question of customs disappears. The part dealing with Customs and Trade Facilitation requires both parties to maintain effective customs controls while respecting intellectual property rights and facilitating faster clearance of legitimate trade. That sentence is at the point where the objectives do not always agree. All exporters gain from quicker clearance; it is possible for effective intellectual property control at the border to appear exactly the same as a shipment being delayed for reasons unrelated to counterfeiting if that control is carelessly applied to a complicated dispute rather than to a clear case of fakes.
Why the border differs from the patent chapter
To remove data exclusivity from a text, a negotiator merely has to make one deletion. A customs officer, on the other hand, cannot clean up a shipment’s problem in such a straightforward way. If a shipment is flagged, the goods must now wait in a warehouse while the authorities decide whether an infringement has occurred. For most cargo, a delay of a few days may not matter much, but for antiretrovirals which have a limited shelf life and vaccines that depend on a cold chain, those few days can decide their shelf life. This is not merely a hypothetical concern. Indian manufacturers faced this problem between 2008 and 2009, and this incident should determine India’s approach to implementation now.
What does TRIPS require at the border
Some observations inaccurately claim that TRIPS never allowed customs to play any role in patent disputes. It matters when India decides how to frame its position. Article 51 of TRIPS requires members to allow right-holders to seek suspension of customs release. But this requirement applies only to counterfeit trademark goods and pirated copyright goods, which the treaty treats as separate categories.
Under that definition, a counterfeit trademark good carries an unauthorised mark that is identical or indistinguishable from a registered trademark. That is a narrower comparison. The treaty leaves it to individual member-countries to decide whether that mandatory procedure should also cover other forms of infringement which include patents. A member can make the procedure stricter if it desires, but the treaty does not require them to do so.
The above distinction matters in practice. A customs officer can usually compare two trademarks without having to resolve difficult questions of law, but comparing a generic medicine for a valid patent claim is entirely different. The interpretation of the claims’ scope, the check to see if the prior art anticipates the invention, the verification that the patent is valid in the country where it is imported, and the determination of whether the generic product falls within the scope of the patent all must be carried out, none of which is like spotting a fake logo. A generic medicine which has the same active ingredient as a patented or branded product is not, on its own, to be regarded as a counterfeit article in the TRIPS sense. It might, depending on the country and the patent, be an infringing good, a question courts themselves take months or years to resolve. Treating those categories as interchangeable at a customs desk, where an officer has hours rather than months, produced the events of 2008.
The Lesson of 2008
Between October 2008 and early 2009, Dutch customs, acting under the EU’s counterfeiting regulation at the time, detained a series of shipments of generic medicines made in India and merely transiting through the Netherlands. Clopidogrel bound for Colombia was seized that October, olanzapine and rivastigmine headed to Peru followed in November, and abacavir purchased by the donor agency UNITAID for HIV treatment in Nigeria was held the same month, released only the following March, after the Dutch government itself acknowledged the time limits for detention had not been respected. The most prominent incident involved around 500 kilograms of Losartan which was bound for Brazil. The shipment was stopped at Schiphol after the holder of a Dutch patent over the branded equivalent raised an objection. None of these medicines infringed any right in India, where they were made, or in the destination countries, where they were headed. The seizures rested on treating goods merely transiting Dutch territory as though manufactured there, and on testing against patents that bore no relation to the medicines’ actual destination.
In May 2010, India and Brazil brought the issue before the WTO and submitted requests for consultations, which were subsequently designated as disputes DS408 and DS409. The matters were settled through consultation rather than by a panel decision, so there is no directly applicable WTO case law. The EU amended its regulation by replacing the previous framework with Regulation 608/2013, which obliges customs authorities to evaluate the risk of diversion before taking action against medicines which were only passing through. However, public health groups regarded this as at best a partial solution since transit shipments had still not been completely excluded from the scope. The more durable protection came from the Court of Justice of the European Union, which, in December 2011, in the joined Nokia and Philips cases, ruled that goods in external transit cannot be treated as infringing simply because they pass through. That action requires actual evidence that the goods are intended for the EU market rather than continuing to their real destination. The case concerned trademarks and designs rather than pharmaceutical patents. Mere transit through a country should not be inherently treated as a diversion.
Current position in India
India has already contended upon this issue within its own legal system and has reached a defensible position. The Intellectual Property Rights Imported Goods Enforcement Rules, 2007, originally let patent holders register complaints with customs alongside trademark and copyright holders. Litigation through the following decade exposed the problem. In 2011, Ericsson filed a customs complaint over standard essential patents, and when the Delhi High Court reviewed the resulting detention, it found that the customs order had not shown a reasoned application of mind to the demands of patent complexity. A related 2012 judgment, between LG Electronics and a patent holder named Bhogilal Patel, went further, noting that a government circular had itself acknowledged that customs authorities are not placed to assess patent or design infringement the way they can assess an obvious trademark or copyright fake. In response, the Central Government introduced the Intellectual Property Rights Imported Goods Enforcement Amendment Rules, 2018, and completely excluded patents from the rules’ definitions, thus ending the customs authorities’ power to deal with patent complaints and directing such disputes instead to the civil court, where proper arguments about the meaning of the claims can be made.
The amendment dealt with one issue but left another unresolved. It was right to decide that customs officers should not determine a patent’s validity at the border. However, it did not specify the procedure to be followed when a genuine generic product, which has been lawfully made in India, is examined by a foreign customs authority that applies the trademark rules of its own country to a product that is only transiting to another place, nor did it provide Indian courts with a domestic diversion test of the kind that the CJEU incorporated into European practice. India excluded patents from its own regime. It has not built a rule for what happens when its exports pass through someone else’s regime under rules that still extend beyond patents to other alleged infringements, including a trademark dispute over packaging.
A framework for implementation
The most useful step India can take before entry into force is not another round of advocacy against provisions already out of the text. It is building a clear, three-part classification structure for how it engages with the agreement’s customs cooperation provisions, and pressing the EU to adopt the same structure in return. The first type involves genuine counterfeit goods bearing an unauthorised copy of a registered trademark. In such cases, border measures are precisely what the TRIPS agreement provides for and what a working system should act upon quickly. The second type is a dispute concerning a contested or ordinary trademark, in which two parties genuinely disagree as to whether the marks are confusingly similar or whether fair use applies, a matter which should be decided by a court and not by automatic seizure. The third is a patent dispute of any kind, which India has already decided does not belong at a customs desk at all. These categories should be separate in customs guidance and in policy discussions with EU authorities. This may reduce the risk of a repeat of the 2008 crisis.
India should also seek a specific rule regarding when a transit shipment can be termed as diverted. Genuine goods in transit could be presumed to be what they claim to be. An objection should require clear evidence and not mere suspicion that the goods were actually diverted into the domestic market. This would give Indian exporters substantial protection without preventing European customs from enforcing its rules.
Practical measures should be relied upon to strengthen both principles. A fixed time limit can also be imposed on detention, and automatic release, unless a court orders otherwise. It can prevent another situation like the Abacavir case where the prescribed time limits were not followed.
Cases involving legal complexity should receive a faster judicial review process. Once the authority accepts that the issue is legally difficult, there is already a strong reason for taking it beyond the customs desk. The Indian Authorised Economic Operator scheme could also be extended to manufacturers with WHO prequalification through a mutual recognition arrangement. Such exporters could then receive faster clearance on the strength of their documentation and compliance record, rather than facing a fresh assessment by a customs officer for every shipment. None of this requires waiting another decade for another WTO dispute. The agreement’s own institutional structure, the Joint Committee and its specialised committees, along with the Rapid Reaction Mechanism for implementation problems, already provides both sides with a forum to work this out while ratification proceeds. Indian officials have reportedly begun reviewing the domestic customs framework in light of the FTA, the right instinct, provided the review keeps patent and trademark questions distinct.
None of this is a criticism of the deal India signed. The patent outcome is a genuine win, which is secured through two decades of a consistent negotiating position. The border issue deserves attention because negotiating an agreement is only the first step and it still has to be implemented. Implementation is where a protection on paper either works in practice or slowly loses its force. India has spent years insisting that a drug without patent rights in India and Brazil should not be treated as an infringing patent that exists only in the Netherlands. Applying the same discipline to customs cooperation will show whether India has actually learned the lesson of 2008.
**Akshat Singh is an Advocate, and has recently graduated from RMLNLU – Lucknow.
**Disclaimer: The views expressed in this blog do not necessarily align with the views of the Vidhi Centre for Legal Policy.